Neutra Considering Move into Clinical Research to Develop New, Better Products
KATY, TX / ACCESSWIRE / June 3, 2021 / Neutra Corp. (OTC PINK:NTRR) is looking into expanding into clinical research as a way to figure out new uses for cannabis, boost its capabilities and come up with new and better CBD products. This proposal comes as the company is enjoying increasing retail success with its current roster of hemp-based CBD lotions, topicals, supplements and gummies.
“We’ve made great progress on our long-term plan for VIVIS and retail CBD sales,” said Neutra CEO Sydney Jim. “But we’re not going to rest on our laurels. We want to ensure this company’s continued success and set the stage for greater prosperity down the road. We believe that adding clinical research to our growing list of corporate capabilities will not only generate new revenues but build additional value for our shareholders and investors.”
Cannabis has seen greater mainstream acceptance. More states have legalized cannabis in some form, either for medicinal use and/or for recreational use as well. Not long ago, cannabis suffered a social stigma and cannabis users faced legal consequences if caught with the substance. Now they can freely use it in a large number of states while the remaining states ponder joining the legalization drive.
Nationwide cannabis sales soared 67% in 2020, according to Flowhub. The cannabis market is expected to grow by an average of 21% over the next several years, reaching $73.6 billion by 2027, says American Cannabis Consulting (ACC). One in five Americans currently uses cannabis in some form and that number will increase over time, analysts project.
About Neutra Corp.
Neutra Corp. (OTC PINK:NTRR) is an early-stage research and development company with a focus on bringing modern healthy living solutions to a multibillion-dollar market. Cutting-edge technologies within the nutraceuticals, food, and drug, and environmental purification sectors are creating a new kind of world culture-one where in which consumers are demanding access to products that promote health and stave off potential health dangers. One of the nutraceutical sub-markets is the new thriving hemp-based CBD market, in which the Company intends to participate. For more information, visit the Company’s website at http://www.NeutraInc.com.
NOTICE REGARDING FORWARD-LOOKING STATEMENTS
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
Neutra Contact:
Sydney Jim
888-433-4033
info@neutrainc.com
SOURCE: Neutra Corp
View source version on accesswire.com:
https://www.accesswire.com/650098/Neutra-Considering-Move-into-Clinical-Research-to-Develop-New-Better-Products
